Breaking Finance News

Zacks Investment Research upgraded Nektar Therapeutics (NASDAQ:NKTR) to Hold in a report released today.

Just yesterday Nektar Therapeutics (NASDAQ:NKTR) traded 0.95% higher at $18.86. Nektar Therapeutics’s 50-day moving average is $18.10 and its 200-day moving average is $15.50. The last stock price is up 23.54% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. 1,307,473 shares of NKTR traded hands, up from an average trading volume of 1,034,180

Zacks Investment Research has upgraded Nektar Therapeutics (NASDAQ:NKTR) to Hold in a report released on Wednesday September 21, 2016.

Recent Performance Chart

Nektar Therapeutics (NASDAQ:NKTR)

Nektar Therapeutics has 52 week low of $9.92 and a 52 week high of $19.98 and has a market capitalization of $0.

Brief Synopsis On Nektar Therapeutics (NASDAQ:NKTR)

Nektar Therapeutics is a biopharmaceutical company. The Company is engaged in the development of a pipeline of drug candidates that utilize its PEGylation and advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. The Company's pipeline consists of drug candidates for therapeutic areas, including oncology, pain, anti-infectives and immunology. The Company's drugs include MOVANTIK (naloxegol) tablets, MOVENTIG, AdYnoVATE, NKTR-102 (next-generation topoisomerase I inhibitor), BAY41-6551 (Amikacin inhale, formerly NKTR-061), NKTR-181 (orally-available mu-opioid analgesic molecule), NKTR-102, NKTR-214 and MoVAnTiK fixed-dose combinations (opioid/naloxegol combinations). Its drugs also include Neulasta (pegfilgrastim), PEGASYS (peginterferon alfa-2a), PEG-INTRON (peginterferon alfa-2b), Somavert (pegvisomant) and Macugen (pegaptanib sodium injection).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.